Cite
MLA Citation
Michele Maio et al.. “P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma.” Journal for immunotherapy of cancer, vol. 8, n.d., pp. A10–A11. http://access.bl.uk/ark:/81055/vdc_100137787055.0x000004